

SUPPLEMENTARY SHEET TO THE PROSPECTUS OF LSP LIFE SCIENCES FUND DATED 26 June 2015

This supplementary sheet forms an integral part of the Prospectus of LSP Life Sciences Fund N.V. dated 26 June 2015.

Sustainable Finance Disclosure Regulation

As of 10 March 2021, the new Sustainable Finance Disclosure Regulation (SFDR) is in effect. The SFDR stems from the European Commission's initiative to promote sustainable investment across the European Union and is part of the EU's 2018 Action Plan on Sustainable Finance.

In order to comply with the SFDR, LSP Advisory B.V. (the Manager) has assessed the environmental, social and governance (ESG) related characteristics of LSP Life Sciences Fund N.V. (the Fund) and makes the following disclosures in order to comply with the SFDR:

Integration of sustainability risks (article 6(1) (a) SFDR)

A sustainability risk means "an environmental, social or governance event or condition that, if it occurs, could cause an actual or potential material negative impact on the value of the investment".

Before an investment decision is made on behalf of a Fund, the Manager follows a structured investment decision process as detailed in the Administrative Organization and Internal Control guide of the Manager. Part of the investment decisions process is that the risk management function of LSP assess the risks attached to a potential investment opportunity, which includes sustainability risks. Identified sustainability risks are taken into account by the Investment Committee of the Fund when making investment decisions.

Likely impact of sustainability risks on return (article 6(1) (b) SFDR)

The Manager has analysed the sustainability risks - including extreme weather events, natural disasters, water crises, spread of infectious diseases and resource scarcity – of the portfolio companies. Mainly based on the geographical location of the portfolio companies and the nature of their development and production processes, the Manager deems the likely impact of sustainability risk on the return of the Fund to be *low*.

Fund level disclosures (article 10 SFDR)

For the purposes of article 10 of the SFDR, the Manager considers that the Fund is a financial product which promotes, among other characteristics, environmental and social characteristics as referred to in article 8 SFDR, and in this respect makes the following disclosures:

i. Environmental and social characteristics

The Fund promotes reducing society's unmet medical need by investing predominantly in companies that are developing treatments for life threatening diseases or serious debilitating conditions.

ii. Good governance

In the fundamental due diligence process of the Fund the prospective portfolio company is assessed on its practices with respect to good governance. Such good governance practices include (i) a sound management structure with a (supervisory) board that monitors the company's executive management, (ii) an appropriate level of employee ownership and (iii) compliance with national and international tax compliance standards.

iii. How the environmental and social characteristics are met

To determine to what extent this societal characteristic is attained, the Fund aggregates the total number of products that address these unmet medical needs across all its portfolio companies.

The abovementioned disclosure pursuant to the SFDR is aligned with information set out in the prospectus with respect to investment criteria, the investment process and risk management procedures and therefore does not constitute a material change therein.

A more detailed disclosure on how the Fund has implemented the SFDR is included on the subsequent pages.

PRODUCT NAME: LSP LIFE SCIENCES FUND NV

ISIN CODE: NL0009756394

LEGAL ENTITY IDENTIFIER: 724500YDP1CL5LKTUK53

This document provides information about the Fund in relation to the Sustainable Finance Disclosure Regulation. It is not marketing material. The information is required to be provided by law to help the recipient understand the sustainability characteristics and/or objectives and risks of the Fund and should be read in conjunction with the other relevant documentation in respect of the Fund so that the recipient can make an informed investment decision.

Environmental and/or social characteristics

Does this financial product have a sustainable investment objective?

Yes

No

It will make a minimum of **sustainable investments with an environmental objective:** __%

in economic activities that qualify as environmentally sustainable under the EU Taxonomy

in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy

It will make a minimum of **sustainable investments with a social objective:** __%

It **promotes Environmental/Social (E/S) characteristics** and while it does not have as its objective a sustainable investment, it will have a minimum proportion of __% of sustainable investments

with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy

with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy

with a social objective

It promotes E/S characteristics, but **will not make any sustainable investments**



What environmental and/or social characteristics are promoted by this financial product?

The Fund promotes reducing society's *unmet medical need* by investing in companies that are developing treatments for life threatening diseases or serious debilitating conditions.

- *What sustainability indicators are used to measure the attainment of each of the environmental or social characteristics promoted by this financial product?*

To determine to what extent this societal characteristic is attained, the Fund rates the pipeline of the portfolio companies on a scale ranging from 1 to 5 according to the extent these products contribute to alleviating the unmet medical need. In addition, the products are classified according to the phase of their development.

An overview of the rating scale is provided below.

	Unmet medical need classification
1	No or very small treatment advantage
2	Modest treatment advantage
3	Considerable treatment advantage
4	Very considerable treatment advantage
5	No alternative treatment



Does this financial product consider principal adverse impacts on sustainability factors?

No.



What investment strategy does this financial product follow?

The Fund targets Investments in companies that demonstrate the following characteristics:

- Availability of one or more highly innovative products or technologies targeting a significant unmet medical and/or commercial need;
- Presence of sustainable competitive advantages and a sound intellectual property position;
- Feasibility of key milestone achievement within pre-defined time frames;
- Attractiveness of valuation as well as key financial and capital markets criteria; and
- High quality management.

- *What are the binding elements of the investment strategy used to select the investments to attain each of the environment or social characteristics promoted by this financial product?*

The Fund will allocate all of its investment capital to companies that address one or more unmet medical needs. In the fundamental due diligence process of the Fund the prospective investee company is assessed on its potential to address unmet medical needs. This is one of the primary criteria in the AIFM's investment decision-making

process. Once an investment has been consummated, the AIFM closely monitors the development of the Investee Company's product pipeline.


In addition, the Fund disregards potential Investee Companies that produce and trade in tobacco and distilled alcohol beverages, weapons or ammunition of any kind, and those that exploit, supply, produce or trade in oil and gas, or casinos or equivalent enterprises.

● *What is the policy to assess good governance practices of the investee companies?*

In the Fund's due diligence process the good governance practices of prospective Investee Companies are assessed. Good governance practices include maintaining: (i) a sound management structure with a supervisory board that monitors the prospective Investee Company's executive management; (ii) an appropriate level of employee ownership; and (iii) compliance with national and international tax compliance standards.



What is the asset allocation planned for this financial product?





Is a specific index designated as a reference benchmark to determine whether this financial product is aligned with the environmental and/or social characteristics that it promotes?

No.



Where can I find more product specific information online?

Further details on the Fund's investment strategy can be found in the Prospectus.